text
stringlengths 1
990
| label
stringlengths 5
2.09k
|
|---|---|
CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCCC(=O)O[C@H](COC(=O)CCCCCCCCC/C=C\C/C=C\C/C=C\CC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCC | The molecule is a proton trap for oxidative phosphorylation and a stabilizing cytochrome oxidase that impacts barth syndrome, diabetic heart disease, and non-alcoholic fatty liver disease. The molecule is a cholesterol translocation, stabilizing mitochondrial structure, apoptosis that impacts aging and tangier disease. |
CCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCC(C)C | The molecule is a stabilizing mitochondrial structure, stabilizing cytochrome oxidase, proton trap for oxidative phosphorylation, cholesterol translocation that impacts non-alcoholic fatty liver disease. The molecule is a apoptosis that impacts diabetic heart disease, barth syndrome, aging, and tangier disease. |
CCCCCCCCCCCCCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCC | The molecule is a nutrient, fat storage, energy storage, membrane stabilizer that impacts cancer and obesity. The molecule is a energy source that impacts both cardiovascular disease and pancreatitis. The molecule is a inflammatory and thyroxine treatment, impacting both metabolic syndrome and atherosclerosis. |
CCCCC/C=C\C/C=C\CCCCCCCCCC(=O)OC[C@@H]1COP(=O)(O)O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@H](C=CC(=O)[C@H](/C=C/[C@@H](O)CCCCC)[C@@H](O)[C@H]2OP(=O)(O)O)C/C=C\CCCC(=O)O1 | It has an effect on colorectal cancer, and impacts diabetes mellitus, cardiovascular disease, and seizure. It has an effect on breast cancer, and impacts alzheimer's disease, stomach cancer, and parkinson's disease. |
O=C(CCNCCc1ccc(O)cc1)NCC(=O)N(CCc1ccccc1)CC(CO)CO | The molecule is a cell adhesion inhibitor. |
CCCCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCC(C)C)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCC | The molecule is a cholesterol translocation, apoptosis, stabilizing cytochrome oxidase that impacts tangier disease and non-alcoholic fatty liver disease. The molecule is a stabilizing mitochondrial structure and a proton trap for oxidative phosphorylation that impacts barth syndrome, diabetic heart disease, and aging. |
CCCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCCC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCC)OC(=O)CCCCCCCCCCCCCCCCC | The molecule is a stabilizing cytochrome oxidase, cholesterol translocation, stabilizing mitochondrial structure that impacts barth syndrome and aging. The molecule is a proton trap for oxidative phosphorylation and a apoptosis that impacts diabetic heart disease, tangier disease, and non-alcoholic fatty liver disease. |
CCCCC/C=C\C/C=C\C/C=C\CCCCC(=O)OCC(COC(=O)CCCC/C=C\C/C=C\C/C=C\CCCCC)OC(=O)CCCCCCCCCCCCCCCCCCCCC | The molecule is thyroxine treatment and it impacts both pancreatitis and cardiovascular disease. The molecule is a nutrient and a fat storage, impacting both atherosclerosis and metabolic syndrome. |
CC(C)(C)OC(=O)N1CCN(C(=O)c2ncn(C3CCCCC3)c2-c2ccccc2)C(Cc2ccccc2)C1 | It impacts hypertension treatment. |
CC12C=CCC=C1CCC1C2CCC2(C)C(C(=O)O)CCC12 | The molecule is a anti inflammatory. |
CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC(C)C)OC(=O)CCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCC(C)CC | The molecule is a proton trap for oxidative phosphorylation and a cholesterol translocation that impacts tangier disease, non-alcoholic fatty liver disease, and barth syndrome. The molecule is a stabilizing mitochondrial structure, apoptosis, stabilizing cytochrome oxidase that impacts diabetic heart disease and aging. |
CCC(C)CCCCCCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCCC(C)C | It impacts metabolic syndrome, atherosclerosis, and cardiovascular disease. The molecule is a thyroxine treatment, a nutrient, and a fat storage, and it impacts pancreatitis. |
CCCCCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCCC(C)C)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC | The molecule is a cholesterol translocation and a stabilizing mitochondrial structure that impacts aging, diabetic heart disease, and tangier disease. The molecule is a proton trap for oxidative phosphorylation, stabilizing cytochrome oxidase, apoptosis that impacts barth syndrome and non-alcoholic fatty liver disease. |
CCCCC/C=C\C/C=C\CCCCCCCCCC(=O)OC[C@H](O)COC(=O)CCCCCCC/C=C\CCCCCCCC | It impacts insulin resistance. |
CCCCCCCCCCCCCCCCCCCCCCCC(=O)OC(COC(=O)CCCCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCCCC | It impacts cardiovascular disease, pancreatitis, and metabolic syndrome. The molecule is a fat storage and a nutrient, impacting both thyroxine treatment and atherosclerosis. |
COC(=O)C1COC(C)C(=O)N1Cc1ccccc1 | The molecule is a thrombin inhibitor. |
CC(CC(=O)c1cc(Cl)c2c(c1)oc(=O)n2C)C(=O)O | The molecule is neurodegenerative treatment. |
CCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCC(C)CC | The molecule is a proton trap for oxidative phosphorylation, apoptosis, cholesterol translocation that impacts non-alcoholic fatty liver disease and tangier disease. The molecule is a stabilizing mitochondrial structure and a stabilizing cytochrome oxidase that impacts barth syndrome, aging, and diabetic heart disease. |
CCCCCCCCCCCCCCCC/C=C/O[C@H](COC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\[C@@H](O)CCCC)COP(=O)(O)OCCN | The molecule is a nutrient that impacts diabetes mellitus type 2, non-alcoholic fatty liver disease, alzheimer's disease, and parkinson's disease. |
CCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCC(C)CC)COC(=O)CCCCCCCCCC(C)C | The molecule is a fat storage, nutrient, and inflammatory that has an effect on cancer and impacts both metabolic syndrome and thyroxine treatment. It impacts obesity, atherosclerosis, and cardiovascular disease. The molecule is a energy source, a membrane stabilizer, and a energy storage, and it impacts pancreatitis. |
CCCCC/C=C\C=C/[C@H](O)C/C=C\C/C=C/CCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCC)COP(=O)([O-])OCC[N+](C)(C)C | The molecule is a nutrient that affects breast cancer by impacting ulcerative colitis, cervical cancer, and atherosclerosis. |
CNC(=O)C(NC(=O)c1nc(C2CCN(S(=O)(=O)c3ccccc3)CC2)n2c1CN(C)CCC2)C(C)(C)C | The molecule is a member of the inflammation treatment class, affects pain treatment, and is characterized as cannabinoid receptor modulator. |
CCc1nn(C)c(C(=O)NCc2ccc(C(C)(C)C)cc2)c1Cl | When heated to decomposition it emits toxic vapors of hydrogen chloride and nitrogen oxides. The molecule has Weak halide technical product/. |
CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CCCCCCCCCCCCCCC | The molecule is a cholesterol translocation that impacts non-alcoholic fatty liver disease, diabetic heart disease, barth syndrome, and aging. The molecule is a proton trap for oxidative phosphorylation, stabilizing mitochondrial structure, apoptosis, stabilizing cytochrome oxidase that impacts tangier disease. |
COc1cccc(-c2nnc(NS(=O)(=O)C(C)C(OC)c3ncc(Cl)cn3)n2CC2CCCC(C)O2)n1 | The molecule is a apj agonist that impacts cardiovascular treatment. |
CCCCCCCC/C=C\CCCCCCCCCCCCCC(=O)O[C@@H](COC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCCCCCC | It impacts atherosclerosis, pancreatitis, and metabolic syndrome. The molecule is a nutrient and fat storage, belonging to the thyroxine treatment class of molecules, and impacts cardiovascular disease. |
CCCCCCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCC)OC(=O)CCCCCCCCCCCCCCCCCCCCC(C)CC | The molecule is a nutrient and thyroxine treatment, impacting metabolic syndrome, cardiovascular disease, obesity, and atherosclerosis. The molecule is a energy storage and energy source, and it impacts cancer. The molecule is a membrane stabilizer, a inflammatory, and a fat storage, and it impacts pancreatitis. |
CC1(C)c2ccccc2-c2cc3c4cc(-n5c6ccccc6c6c7c(ccc65)C(C)(C)C(C)(C)C7(C)C)ccc4n(-c4ccccc4)c3cc21 | The molecule is a phosphorescent emitter and belongs to the organic electroluminescent device class of molecules; it is phosphorescent and electroluminescent. |
CCC(/C=C/C(C)C1CCC2C3CC(=O)C4CC(=O)CCC4(C)C3CCC12C)C(C)C | The molecule is a energy source, emulsifier, surfactant, energy storage, nutrient, membrane stabilizer. |
CCC(C)CCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCC(C)C)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCC(C)C | The molecule is a apoptosis and a food additive, impacting both aging and tangier disease. The molecule is a stabilizing cytochrome oxidase, membrane stabilizer, energy source, surfactant, and smooth. The molecule is a energy storage, a emulsifier, and a cholesterol translocation, and it impacts barth syndrome. The molecule is a nutritional supplement, proton trap for oxidative phosphorylation, stabilizing mitochondrial structure that impacts non-alcoholic fatty liver disease and diabetic heart disease. |
CCCCCCCC/C=C/C/C=C/C=C/C(O)CCCC(=O)O[C@H](COC(=O)CCCCCCCCCCc1oc(CCC)c(C)c1C)COP(=O)([O-])OCC[N+](C)(C)C | The molecule is a nutrient that affects cervical cancer by impacting breast cancer, ulcerative colitis, and atherosclerosis. |
CCCCCCCCCCCCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCCCC(C)CC)OC(=O)CCCCCCCCCCCCC | The molecule is a inflammatory and a energy source that impacts thyroxine treatment, metabolic syndrome, cardiovascular disease, and obesity. The molecule is a fat storage and nutrient with an effect on cancer. The molecule is a membrane stabilizer and a energy storage, impacting both atherosclerosis and pancreatitis. |
CC(CCNc1cccc2c1C(=O)N(C1CCC(=O)NC1=O)C2=O)OC1CCN(C(=O)OC(C)(C)C)CC1 | The molecule is a treatment of disorder. |
CC(=O)NCCc1nc(C(=O)N2CCc3c(ccc(N(C)C)c3O)C2)c2ccccc2n1 | It impacts tumor treatment. |
NC(=O)c1csc2c(NC3CCNC3)nc(-c3ccncc3)nc12 | The molecule is a protein kinase inhibitor. |
c1ccc(N(c2ccc(-c3ccc(-n4c5ccccc5c5c6ccccc6ccc54)cc3)cc2)c2ccc3oc4ccccc4c3c2)cc1 | The molecule is light-emitting and it impacts luminous efficiency. |
CCCCCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCC(C)C)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCC)OC(=O)CCCCCCCCCCC(C)C | The molecule is a apoptosis and a cholesterol translocation that impacts non-alcoholic fatty liver disease, diabetic heart disease, and tangier disease. The molecule is a proton trap for oxidative phosphorylation, stabilizing mitochondrial structure, stabilizing cytochrome oxidase that impacts aging and barth syndrome. |
CC1(C)OCC(COc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2N)O1 | The molecule is both a egfr inhibitor and a cancer treatment. |
COc1cnc(CC(=O)Nc2cc(C3CCC(OC(=O)N4CCC4(C)C)C3)[nH]n2)cn1 | It impacts cancer treatment. |
CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCC/C=C\CCCCCC)OC(=O)CCCCCCC/C=C\CCCCCCCC)OC(=O)CCCCCCC/C=C\CCCCCCCC | The molecule is a cholesterol translocation, a proton trap for oxidative phosphorylation, a energy source, and smooth. The molecule is a stabilizing mitochondrial structure, stabilizing cytochrome oxidase, emulsifier, apoptosis that impacts non-alcoholic fatty liver disease. The molecule is a nutritional supplement, a energy storage, and a membrane stabilizer, and it impacts tangier disease. The molecule is a food additive and a surfactant that impacts barth syndrome, diabetic heart disease, and aging. |
CC(C)(OC1OC(CO)C(O)C(O)C1O)c1cc2c(ccc3ccc(=O)oc32)o1 | The molecule is a nutrient. |
Cc1c(CCC(=O)NCCCc2ccccc2)nc2ccccc2c1OCc1ccccc1 | The molecule is diabetes treatment. |
CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC/C=C\C/C=C\C/C=C\CC)OC(=O)CCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CCCCCCCCC/C=C\C/C=C\C/C=C\CC | The molecule is a cholesterol translocation that impacts tangier disease, barth syndrome, aging, and non-alcoholic fatty liver disease. The molecule is a stabilizing cytochrome oxidase, proton trap for oxidative phosphorylation, stabilizing mitochondrial structure, apoptosis that impacts diabetic heart disease. |
CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)O[C@H](COC(=O)CCCCCCC/C=C\CCCCCC)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCC/C=C\C/C=C\C/C=C\C/C=C\CC)OC(=O)CCCCCCCCC/C=C\C/C=C\C/C=C\CC | The molecule is a proton trap for oxidative phosphorylation that impacts barth syndrome, tangier disease, diabetic heart disease, and aging. The molecule is a apoptosis, stabilizing mitochondrial structure, stabilizing cytochrome oxidase, cholesterol translocation that impacts non-alcoholic fatty liver disease. |
CCCCCC/C=C\C=C/CCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC(C)CC)OC(=O)CCCCCCCCCCCCCCCCCCCCCCC | The molecule is a stabilizing mitochondrial structure, proton trap for oxidative phosphorylation, stabilizing cytochrome oxidase that impacts tangier disease and non-alcoholic fatty liver disease. The molecule is a cholesterol translocation and a apoptosis that impacts aging, diabetic heart disease, and barth syndrome. |
O=C(O)c1ccc(C(=O)O)nc1.O=S(=O)(O)c1ccccc1 | The molecule is both a pain treatment and a cox2 inhibitor. |
CCCCCCCCCCCCCCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCCCCCCC(C)CC)OC(=O)CCCCCCCCCCCCCCCCCC(C)C | The molecule is a energy source and a membrane stabilizer that impacts cardiovascular disease, metabolic syndrome, obesity, and pancreatitis. The molecule is a inflammatory and a nutrient, belonging to the thyroxine treatment class of molecules. The molecule is a energy storage and a fat storage, with effects on cancer and impacts on atherosclerosis. |
COc1cc2c(c3oc(=O)ccc13)C(OC)C(O)C(C)(C)O2 | The molecule is a nutrient. |
CCCCCCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCCCCCC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCC)OC(=O)CCCCCCCCCCCC | The molecule is a proton trap for oxidative phosphorylation and a stabilizing cytochrome oxidase that impacts non-alcoholic fatty liver disease, diabetic heart disease, and aging. The molecule is a stabilizing mitochondrial structure, cholesterol translocation, apoptosis that impacts barth syndrome and tangier disease. |
CCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCC)OC(=O)CCCCCCCCCCCC | The molecule is a stabilizing mitochondrial structure and a proton trap for oxidative phosphorylation that impacts non-alcoholic fatty liver disease, tangier disease, and barth syndrome. The molecule is a stabilizing cytochrome oxidase, apoptosis, cholesterol translocation that impacts aging and diabetic heart disease. |
CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COC(=O)CCCCCCCCCCCC(C)C)COC(=O)CCCCCCCCCCC(C)CC | The molecule is a fat storage and a energy storage, which has an effect on cancer and impacts both metabolic syndrome and cardiovascular disease, while being thyroxine treatment. The molecule is a membrane stabilizer and nutrient, and it impacts obesity. The molecule is a inflammatory and a energy source, impacting both pancreatitis and atherosclerosis. |
CCCCCCCC/C=C\C/C=C\C/C=C\CCCC(=O)OC[C@H](COP(=O)(O)O[C@H]1C(O)C(O)C(O)[C@@H](OP(=O)(O)O)C1O)OC(=O)CCCCCCC/C=C\CC1OC1CCCCC | It has an effect on stomach cancer, and impacts seizure, cardiovascular disease, and breast cancer. It has an effect on colorectal cancer, and impacts diabetes mellitus, alzheimer's disease, and parkinson's disease. |
CCCCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCC(C)CC | The molecule is a cholesterol translocation and a proton trap for oxidative phosphorylation that impacts non-alcoholic fatty liver disease, tangier disease, and diabetic heart disease. The molecule is a stabilizing cytochrome oxidase, stabilizing mitochondrial structure, apoptosis that impacts aging and barth syndrome. |
CCCCCCCC/C=C\CCCCCC/C=C/O[C@H](COC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\[C@@H](O)CCCC)COP(=O)([O-])OCC[N+](C)(C)C | The molecule is a nutrient that affects cervical cancer by impacting ulcerative colitis, atherosclerosis, and breast cancer. |
Cn1c(=O)ccc2cccc(OS(=O)(=O)C(F)(F)F)c21 | The molecule is anti bacterial. |
COc1cc(/C=C/C(=O)OC2C(OC3C(Oc4cc(O)c5c(=O)cc(-c6cc(OC)c(O)c(OC)c6)oc5c4)OC(C(=O)O)C(O)C3O)OC(C(=O)O)C(O)C2O)ccc1O | The molecule is a nutrient. |
CCCCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCC(C)CC)OC(=O)CCCCCCCCCCCCCCCCC | The molecule is a apoptosis, stabilizing mitochondrial structure, stabilizing cytochrome oxidase that impacts tangier disease and non-alcoholic fatty liver disease. The molecule is a proton trap for oxidative phosphorylation and a cholesterol translocation that impacts diabetic heart disease, barth syndrome, and aging. |
CC=CCC1=C(C)C(OC(=O)C2C(C=C(C)C)C2(C)C)CC1=O | Pyrethrins are decomp by exposure to light with loss of insecticidal activity. pyrethrins/ |
CCCCCCCCCCCCCCCCCCC(=O)O[C@@H](COC(=O)CCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC(C)CC | The molecule is a energy storage and thyroxine treatment, affecting cancer, and impacting cardiovascular disease, atherosclerosis, and pancreatitis. The molecule is a nutrient, a fat storage, and a membrane stabilizer. The molecule is a energy source and a inflammatory, impacting both metabolic syndrome and obesity. |
CCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCC)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCCCCCC(C)C | The molecule is a stabilizing cytochrome oxidase and a proton trap for oxidative phosphorylation that impacts non-alcoholic fatty liver disease, diabetic heart disease, and aging. The molecule is a cholesterol translocation, stabilizing mitochondrial structure, apoptosis that impacts tangier disease and barth syndrome. |
CCCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCC | The molecule is a cholesterol translocation, apoptosis, stabilizing mitochondrial structure that impacts diabetic heart disease and tangier disease. The molecule is a proton trap for oxidative phosphorylation and a stabilizing cytochrome oxidase that impacts aging, barth syndrome, and non-alcoholic fatty liver disease. |
CC1CCC(Nc2nc(CI)nc3ccccc23)CC1 | It belongs to the anti cancer agent class of molecules. |
C=Cn1ccnc1.CCCC(CC)Oc1ccc(C=CC(=O)O)cc1 | The molecule is a corrosion inhibitor. |
CCC1(C#N)CCN(c2ccnc(Nc3cnn(C4CN(C(=O)CC#N)C4)c3)n2)C1=O | The molecule is both a autoimmune disease treatment and a tyk2 inhibitor. |
CCCCCC/C=C\CCCCCCCCCC(=O)OC[C@@H]1COP(=O)(O)O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CCCCCCC(=O)O1)C(=O)C[C@@H](O)[C@H](/C=C\[C@@H](O)CCCCC)[C@@H](O)[C@H]2OP(=O)(O)O | It has an effect on colorectal cancer, and impacts cardiovascular disease, diabetes mellitus, and parkinson's disease. It has an effect on stomach cancer, and impacts breast cancer, seizure, and alzheimer's disease. |
CCCC(C)(COC(N)=O)COC(N)=O | When heated to decomp it emits toxic fumes of nitrogen oxides./ The molecule has both a Characteristic odor and a Characteristic bitter taste. |
CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)O[C@H](COC(=O)CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCC)COC(=O)CCCCCCCCC/C=C\C/C=C\CCCCC | The molecule is a fat storage that impacts both metabolic syndrome and atherosclerosis. The molecule is a nutrient and belongs to the thyroxine treatment class of molecules, impacting both pancreatitis and cardiovascular disease. |
CCCCCCCCCCCCCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCCCCCC(C)C | The molecule is a energy source and a nutrient, which impacts pancreatitis, cardiovascular disease, and obesity, and is characterized as thyroxine treatment. The molecule is a membrane stabilizer, a energy storage, and a inflammatory. The molecule is a fat storage that impacts atherosclerosis, cancer, and metabolic syndrome. |
CCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCC(C)C)COC(=O)CCCCCCCCCCCC(C)C | The molecule is a membrane stabilizer, nutrient, fat storage that impacts metabolic syndrome, pancreatitis, and cardiovascular disease. The molecule is a thyroxine treatment and inflammatory with an effect on cancer. The molecule is a energy storage and a energy source, impacting both obesity and atherosclerosis. |
COc1cc(C(=O)NCC(=O)N2CCN(C(=O)CCC(=O)O)CC2)nc2ccccc12 | It belongs to the anti thrombotic class of molecules. |
CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCC)OC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC)OC(=O)CCCCCCCCC/C=C\C/C=C\C/C=C\CC | The molecule is a cholesterol translocation and a apoptosis that impacts aging, diabetic heart disease, and non-alcoholic fatty liver disease. The molecule is a proton trap for oxidative phosphorylation, stabilizing mitochondrial structure, stabilizing cytochrome oxidase that impacts barth syndrome and tangier disease. |
CCC(C)CCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCC(C)CC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCCCC(C)C | The molecule is a nutritional supplement that impacts diabetic heart disease, tangier disease, and aging. The molecule is a food additive, apoptosis, stabilizing cytochrome oxidase, energy storage that impacts barth syndrome. The molecule is a stabilizing mitochondrial structure, a energy source, a proton trap for oxidative phosphorylation, and smooth. The molecule is a surfactant, emulsifier, cholesterol translocation, membrane stabilizer that impacts non-alcoholic fatty liver disease. |
CCCCCCCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCCCCCC(C)C | The molecule is a cholesterol translocation, stabilizing cytochrome oxidase, stabilizing mitochondrial structure that impacts diabetic heart disease and non-alcoholic fatty liver disease. The molecule is a apoptosis and a proton trap for oxidative phosphorylation that impacts tangier disease, barth syndrome, and aging. |
CCC(C)Cc1ccc(C(=O)Oc2ccc(C(=O)Cl)cc2)cc1 | The molecule is a liquid crystal. |
CC/C=C\C/C=C\C/C=C\C/C=C\CCCCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CCCCCCC/C=C\CCCCCC)OC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\CCCCC | The molecule is a cholesterol translocation, stabilizing cytochrome oxidase, apoptosis that impacts tangier disease and non-alcoholic fatty liver disease. The molecule is a proton trap for oxidative phosphorylation and a stabilizing mitochondrial structure that impacts aging, barth syndrome, and diabetic heart disease. |
CCC(C)CCCCCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCC(C)C | The molecule is a membrane stabilizer and a apoptosis, impacting both barth syndrome and aging. The molecule is a stabilizing mitochondrial structure, proton trap for oxidative phosphorylation, energy storage, surfactant, and smooth. The molecule is a cholesterol translocation and a food additive, impacting both tangier disease and diabetic heart disease. The molecule is a energy source, nutritional supplement, stabilizing cytochrome oxidase, emulsifier that impacts non-alcoholic fatty liver disease. |
CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)O[C@H](COCCCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCC | The molecule is a nutrient and fat storage, and it impacts pancreatitis. It impacts thyroxine treatment, atherosclerosis, cardiovascular disease, and metabolic syndrome. |
CCNc1ccc(C=CC(=O)O)cn1 | The molecule is both a pak inhibitor and a anti cancer. |
CCn1cc(CCCOC)c2cc(C(C)NC3CC3)ncc21 | The molecule is a renin inhibitor. |
NC(=O)c1ccc(Cn2ccc3cc(CNCCO)ccc32)cc1 | It impacts obesity treatment. |
CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC | The molecule is a stabilizing mitochondrial structure, apoptosis, cholesterol translocation, nutritional supplement. The molecule is a energy storage and a membrane stabilizer that impacts diabetic heart disease, non-alcoholic fatty liver disease, and aging. The molecule is a surfactant, a emulsifier, and a energy source, and it impacts barth syndrome. The molecule is a proton trap for oxidative phosphorylation, a food additive, and a stabilizing cytochrome oxidase, it impacts tangier disease and is smooth. |
CCCCCCCC/C=C\CCCCCCCC(=O)OC(COC(=O)CCCCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCCCC | The molecule is a nutrient that impacts both pancreatitis and metabolic syndrome. The molecule is a fat storage that impacts atherosclerosis, cardiovascular disease, and thyroxine treatment. |
CC(=O)OCP(=O)(O)O.O=C1CCN1 | The molecule is a anti bacterial and belongs to the anti biotic class of molecules. |
COc1cc(OCCCC(=O)OC(=O)c2c(-c3cccs3)noc2NC(C)=O)ccc1CNc1ccccc1 | The molecule is a kinase inhibitor. |
CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC | The molecule is a apoptosis, stabilizing mitochondrial structure, cholesterol translocation that impacts diabetic heart disease and barth syndrome. The molecule is a stabilizing cytochrome oxidase and a proton trap for oxidative phosphorylation that impacts tangier disease, non-alcoholic fatty liver disease, and aging. |
CC(C)CCCCCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCC(C)C | The molecule is a apoptosis, a energy storage, and a energy source, and it impacts barth syndrome. The molecule is a emulsifier and a cholesterol translocation, which impacts both tangier disease and aging, and is characterized as smooth. The molecule is a stabilizing mitochondrial structure, stabilizing cytochrome oxidase, surfactant, membrane stabilizer. The molecule is a proton trap for oxidative phosphorylation, nutritional supplement, food additive that impacts diabetic heart disease and non-alcoholic fatty liver disease. |
CCCCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)O[C@H](COC(=O)CCCCCCC/C=C\CCCCCC)COC(=O)CCCCCCCCCCCCCCCCCCCCC | The molecule is a thyroxine treatment and nutrient, and it impacts metabolic syndrome. The molecule is a fat storage that impacts cardiovascular disease, atherosclerosis, and pancreatitis. |
CC/C=C\CC(O)/C=C/C=C/C/C=C\C/C=C\C/C=C\CCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCCCCCCCCCCCCCC | The molecule is a nutrient that impacts non-alcoholic fatty liver disease, diabetes mellitus type 2, parkinson's disease, and alzheimer's disease. |
CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCC/C=C\CCCCCCCC)OC(=O)CCCCCCCCC/C=C\C/C=C\C/C=C\CC)OC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC | The molecule is a apoptosis, cholesterol translocation, proton trap for oxidative phosphorylation that impacts non-alcoholic fatty liver disease and tangier disease. The molecule is a stabilizing mitochondrial structure and a stabilizing cytochrome oxidase that impacts diabetic heart disease, aging, and barth syndrome. |
CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCC)OC(=O)CCCCCCCCC/C=C\C/C=C\C/C=C\CC | The molecule is a apoptosis and a proton trap for oxidative phosphorylation that impacts tangier disease, non-alcoholic fatty liver disease, and barth syndrome. The molecule is a cholesterol translocation, stabilizing cytochrome oxidase, stabilizing mitochondrial structure that impacts diabetic heart disease and aging. |
CCCCCCCCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCC/C=C\C[C@H]1C(=O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)CCCCC | The molecule is a nutrient that affects both cervical cancer and breast cancer, and also impacts ulcerative colitis and atherosclerosis. |
CCCCCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCC(C)C | The molecule is a nutrient, fat storage, energy source that impacts obesity, pancreatitis, and cancer. The molecule is a inflammatory and membrane stabilizer, and it impacts metabolic syndrome. The molecule is a energy storage and belongs to the thyroxine treatment class of molecules, impacting both atherosclerosis and cardiovascular disease. |
CC(C)CCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCC(C)C)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCC(C)C)OC(=O)CCCCCCCCC(C)C | The molecule is a proton trap for oxidative phosphorylation, membrane stabilizer, stabilizing mitochondrial structure, nutritional supplement. The molecule is a food additive and smooth, impacting barth syndrome, tangier disease, and diabetic heart disease. The molecule is a energy storage, energy source, apoptosis, cholesterol translocation. The molecule is a emulsifier, surfactant, stabilizing cytochrome oxidase that impacts non-alcoholic fatty liver disease and aging. |
O=[Cr](=O)([O-])[O-].[Zn+2] | The molecule has Odorless. Substance itself does not burn but may decompose upon heating to produce corrosive and/or toxic fumes. |
CC/C=C\C/C=C\C/C=C\CCCCCCCC(=O)O[C@H](COC(=O)CCC/C=C\C/C=C\C/C=C\CCCCCCCC)COC(=O)CCCCCCCCC/C=C\CCCCCC | The molecule is a member of the thyroxine treatment class and affects both metabolic syndrome and atherosclerosis. The molecule is a fat storage and a nutrient, impacting both cardiovascular disease and pancreatitis. |
Cc1ccc(S(=O)(=O)n2cc(I)c3c(C4=CCCC(NC(=O)O)C4)ccnc32)cc1 | The molecule is a jak3 inhibitor. |
CCCCCCCC/C=C\C/C=C\C/C=C\CCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCC)COP(=O)(O)OCCN | The molecule is a nutrient that impacts alzheimer's disease, parkinson's disease, diabetes mellitus type 2, and non-alcoholic fatty liver disease. |
O=S(=O)(NS(=O)(=O)C(F)(C(F)(F)F)C(F)(F)F)c1c(F)c(F)c(F)c(F)c1F | It belongs to the organic electronic device class of molecules. |
COc1cc(C(O)C(Cn2cc3cc(C(F)(F)F)cc(C(=O)O)c3n2)OC2CCCC2)cc(OC)c1C | The molecule is a lpa antagonist. |
CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CCCCCCC/C=C\CCCCCCCC)OC(=O)CCCCCCCCC/C=C\C/C=C\CCCCC | The molecule is a stabilizing mitochondrial structure, stabilizing cytochrome oxidase, proton trap for oxidative phosphorylation that impacts barth syndrome and tangier disease. The molecule is a cholesterol translocation and a apoptosis that impacts diabetic heart disease, non-alcoholic fatty liver disease, and aging. |